Lionshead Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$822K Buy
29,266
+32
+0.1% +$852 0.61% 48
2025
Q4
$728K Buy
29,234
+35
+0.1% +$883 0.55% 48
2025
Q3
$744K Buy
29,199
+4,296
+17% +$106K 0.59% 45
2025
Q2
$604K Buy
24,903
+219
+0.9% +$5.11K 0.56% 51
2025
Q1
$625K Sell
24,684
-2,320
-9% -$60.7K 0.65% 44
2024
Q4
$716K Buy
+27,004
New +$732K 0.52% 44

Other funds holding PFE

Lionshead Wealth Management's PFE Position: Q1 2026 in Review

Lionshead Wealth Management increased its Pfizer (PFE) stake by 0.11% in Q1 2026, buying an estimated $852 and bringing the position to 29,266 shares worth $822K. The position accounts for 0.61% of the portfolio, ranked #48.

Lionshead Wealth Management first reported a position in PFE in Q4 2024 and has held it in 6 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Lionshead Wealth Management held 29,266 shares of Pfizer worth $822K as of Q1 2026.
  • Lionshead Wealth Management bought 32 Pfizer shares in Q1 2026, an estimated $852.
  • Pfizer made up 0.61% of Lionshead Wealth Management's portfolio in Q1 2026, its #48 holding.
  • Lionshead Wealth Management first reported a position in Pfizer in Q4 2024 and has held it in 6 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Lionshead Wealth Management's 13F filing for Q1 2026, filed 11 May 2026.